Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: biodefense

PharmAthene gets FDA nod on SparVax

PharmAthene Inc., of Annapolis, a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Food and Drug Administration has lifted a nearly-10-month hold placed on a proposed Phase II study of SparVax, allowing a clinical trial of the next-generation anthrax vaccine to proceed.

Read More »

Tough medicine: Court rules firm may get $100M

Annapolis-based PharmAthene Inc. may be entitled to at least $100 million in damages after the Delaware Supreme Court held that Siga Technologies Inc. acted in bad faith in backing out of a proposed licensing agreement for its smallpox treatment medication to be used in response to a biochemical attack.

Read More »